Don’t let the public pronouncements of pain for pharma from healthcare reform confuse you. Big pharma has had the expansion of health insurance and finding deep pockets to cover the uninsured as its major goal for years. Pharma execs and policy people are trying to sound worried; it is hard.
Cole Werble
Sometimes, it's tough for pharma execs to rein in their exuberance about the big new market awaiting the industry on...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.
Vinay Prasad’s exit from the US FDA reignited conversations about integrating its drugs and biologics centers under George Tidmarsh. Those plans appear to be shelved, but the leadership transition could be an opportunity to fully realize the vision for the Oncology Center of Excellence.
The Pink Sheet viewed Stealth's complete response letter and other documents indicating the FDA appears willing to grant accelerated approval to elamipretide before a confirmatory trial begins enrolling. But the company says it needs a two-month review of the NDA resubmission to survive.
